CALHM1 P86L 多态性不会改变脑脊液中的淀粉样蛋白-β或tau。
CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid.
机构信息
Uppsala University, Department of Public Health/Geriatrics, Rudbeck Laboratory, Uppsala, Sweden.
出版信息
Neurosci Lett. 2010 Jan 22;469(2):265-7. doi: 10.1016/j.neulet.2009.12.011. Epub 2009 Dec 23.
Abstract
Recently, the P86L alteration in CALHM1 (calcium homeostasis modulator-1) was reported to be associated with Alzheimer's disease (AD). Moreover, the risk allele increased amyloid-beta (A beta) levels in conditioned media from cultured cells. Therefore, we hypothesized that CALHM1 P86L may modulate A beta or tau levels in cerebrospinal fluid (CSF). Nearly 200 individuals with AD or other cognitive disorders were included for CSF analysis and CALHM1 genotyping. No significant differences in CSF levels of A beta 42, tau or phospho-tau were found across the various CALHM1 genotypes. In conclusion, we found no evidence that CALHM1 P86L is associated with altered CSF levels of the investigated AD biomarkers.
摘要
最近，CALHM1（钙稳态调节剂-1）中的 P86L 改变与阿尔茨海默病（AD）有关。此外，风险等位基因增加了培养细胞条件培养基中的淀粉样蛋白-β（Aβ）水平。因此，我们假设 CALHM1 P86L 可能调节脑脊液（CSF）中的 Aβ或 tau 水平。将近 200 名患有 AD 或其他认知障碍的个体被纳入 CSF 分析和 CALHM1 基因分型。在不同的 CALHM1 基因型中，Aβ42、tau 或磷酸化 tau 的 CSF 水平没有显著差异。总之，我们没有发现证据表明 CALHM1 P86L 与所研究的 AD 生物标志物的 CSF 水平改变有关。
相似文献
1
CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid.
Neurosci Lett. 2010 Jan 22;469(2):265-7. doi: 10.1016/j.neulet.2009.12.011. Epub 2009 Dec 23.
2
CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease.
Mol Med. 2011 Sep-Oct;17(9-10):974-9. doi: 10.2119/molmed.2011.00154. Epub 2011 May 24.
3
CALHM1 and its polymorphism P86L differentially control Ca²⁺homeostasis, mitogen-activated protein kinase signaling, and cell vulnerability upon exposure to amyloid β.
Aging Cell. 2015 Dec;14(6):1094-102. doi: 10.1111/acel.12403. Epub 2015 Sep 29.
4
Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis.
PLoS One. 2013 Sep 17;8(9):e74203. doi: 10.1371/journal.pone.0074203. eCollection 2013.
5
Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels.
J Alzheimers Dis. 2010;21(3):833-42. doi: 10.3233/JAD-2010-091711.
6
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study.
J Alzheimers Dis. 2010;22(1):247-55. doi: 10.3233/JAD-2010-100933.
7
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.
8
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.
9
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk.
Cell. 2008 Jun 27;133(7):1149-61. doi: 10.1016/j.cell.2008.05.048.
10
Mitochondria sense with different kinetics the calcium entering into HeLa cells through calcium channels CALHM1 and mutated P86L-CALHM1.
Biochem Biophys Res Commun. 2010 Jan 1;391(1):722-6. doi: 10.1016/j.bbrc.2009.11.127. Epub 2009 Nov 26.
引用本文的文献
1
CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice.
Sci Rep. 2016 Apr 12;6:24250. doi: 10.1038/srep24250.
2
CALHM1 ion channel elicits amyloid-β clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain.
J Cell Sci. 2015 Jul 1;128(13):2330-8. doi: 10.1242/jcs.167270. Epub 2015 May 21.
3
Effect of the CALHM1 G330D and R154H human variants on the control of cytosolic Ca2+ and Aβ levels.
PLoS One. 2014 Nov 11;9(11):e112484. doi: 10.1371/journal.pone.0112484. eCollection 2014.
4
Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation.
PLoS Genet. 2014 Oct 23;10(10):e1004758. doi: 10.1371/journal.pgen.1004758. eCollection 2014 Oct.
5
CALHM1 controls the Ca²⁺-dependent MEK, ERK, RSK and MSK signaling cascade in neurons.
J Cell Sci. 2013 Mar 1;126(Pt 5):1199-206. doi: 10.1242/jcs.117135. Epub 2013 Jan 23.
6
Generation of Calhm1 knockout mouse and characterization of calhm1 gene expression.
Protein Cell. 2012 Jun;3(6):470-80. doi: 10.1007/s13238-012-2932-6. Epub 2012 Jun 21.
7
CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease.
Mol Med. 2011 Sep-Oct;17(9-10):974-9. doi: 10.2119/molmed.2011.00154. Epub 2011 May 24.
8
Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels.
J Alzheimers Dis. 2010;21(3):833-42. doi: 10.3233/JAD-2010-091711.
本文引用的文献
1
No association between CALHM1 and risk for Alzheimer dementia in a Belgian population.
Hum Mutat. 2009 Apr;30(4):E570-4. doi: 10.1002/humu.20990.
2
No association between CALHM1 variation and risk of Alzheimer disease.
Hum Mutat. 2009 Apr;30(4):E566-9. doi: 10.1002/humu.20989.
3
No association between CALHM1 and Alzheimer's disease risk.
Cell. 2008 Dec 12;135(6):993-4; author reply 994-6. doi: 10.1016/j.cell.2008.11.030.
4
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk.
Cell. 2008 Jun 27;133(7):1149-61. doi: 10.1016/j.cell.2008.05.048.
5
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
Neurology. 2007 May 8;68(19):1603-6. doi: 10.1212/01.wnl.0000260969.94695.56.
6
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.
Nat Genet. 2007 Jan;39(1):17-23. doi: 10.1038/ng1934.
7
Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Biol Psychiatry. 2004 Nov 1;56(9):670-6. doi: 10.1016/j.biopsych.2004.07.021.
8
Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease.
Hum Genet. 2004 May;114(6):581-7. doi: 10.1007/s00439-004-1107-9. Epub 2004 Mar 18.
9
Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.
Neurobiol Aging. 2000 Sep-Oct;21(5):735-40. doi: 10.1016/s0197-4580(00)00164-0.
10
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
Arch Neurol. 1998 Jul;55(7):937-45. doi: 10.1001/archneur.55.7.937.
Zotero 插件